GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (NAS:RGLS) » Definitions » Shiller PE Ratio

Regulus Therapeutics (Regulus Therapeutics) Shiller PE Ratio : (As of May. 15, 2024)


View and export this data going back to 2012. Start your Free Trial

What is Regulus Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Regulus Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Regulus Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regulus Therapeutics Shiller PE Ratio Chart

Regulus Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Regulus Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Regulus Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Regulus Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Regulus Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Regulus Therapeutics's Shiller PE Ratio falls into.



Regulus Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Regulus Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Regulus Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.29/129.4194*129.4194
=-0.290

Current CPI (Mar. 2024) = 129.4194.

Regulus Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -34.800 100.560 -44.787
201409 -31.200 100.428 -40.207
201412 -56.400 99.070 -73.678
201503 -34.800 99.621 -45.209
201506 -49.200 100.684 -63.242
201509 -30.000 100.392 -38.674
201512 -16.800 99.792 -21.788
201603 -48.000 100.470 -61.830
201606 -48.000 101.688 -61.090
201609 -44.400 101.861 -56.412
201612 -45.600 101.863 -57.936
201703 -45.600 102.862 -57.373
201706 -49.200 103.349 -61.611
201709 -21.100 104.136 -26.223
201712 -16.800 104.011 -20.904
201803 -18.500 105.290 -22.740
201806 -15.900 106.317 -19.355
201809 -11.800 106.507 -14.339
201812 -9.800 105.998 -11.965
201903 -3.100 107.251 -3.741
201906 -3.000 108.070 -3.593
201909 -2.600 108.329 -3.106
201912 -2.300 108.420 -2.745
202003 -2.500 108.902 -2.971
202006 -2.300 108.767 -2.737
202009 -0.400 109.815 -0.471
202012 -0.300 109.897 -0.353
202103 -0.800 111.754 -0.926
202106 -0.780 114.631 -0.881
202109 -0.990 115.734 -1.107
202112 -0.700 117.630 -0.770
202203 -0.460 121.301 -0.491
202206 -0.500 125.017 -0.518
202209 -0.500 125.227 -0.517
202212 -0.400 125.222 -0.413
202303 -0.420 127.348 -0.427
202306 -0.370 128.729 -0.372
202309 -0.400 129.860 -0.399
202312 -0.390 129.419 -0.390
202403 -0.290 129.419 -0.290

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Regulus Therapeutics  (NAS:RGLS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Regulus Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Regulus Therapeutics (Regulus Therapeutics) Business Description

Traded in Other Exchanges
Address
4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121
Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. MicroRNA is a noncoding ribonucleic acid that regulates most genes in the genome. The company partnered with Sanofi to create a compound targeting orphan diseases and with AstraZeneca to cure Type 2 Diabetes/prediabetes.
Executives
Crispina Calsada officer: Chief Financial Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Christopher Ray Aker officer: Sr. VP & General Counsel C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Joseph P Hagan officer: Chief Operating Officer 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Preston Klassen officer: President & Head of R & D 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Denis Drygin officer: Chief Scientific Officer 10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Alice Shih-hou Huang director 10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Ali Behbahani 10 percent owner 5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Forest Baskett 10 percent owner
Joshua Makower 10 percent owner 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Paul Edward Walker director 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Carmen Chang 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Scott D Sandell 10 percent owner

Regulus Therapeutics (Regulus Therapeutics) Headlines

From GuruFocus

Regulus Therapeutics Announces Resignation of Board Member

By PRNewswire PRNewswire 12-12-2022